<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02335957</url>
  </required_header>
  <id_info>
    <org_study_id>GIC-RAD-2014-02</org_study_id>
    <nct_id>NCT02335957</nct_id>
  </id_info>
  <brief_title>OPTimizing Irradiation Through Molecular Assessment of Lymph Node (OPTIMAL)</brief_title>
  <acronym>OPTIMAL</acronym>
  <official_title>OPTimizing Irradiation Through Molecular Assessment of Lymph Node (OPTIMAL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo de Investigación Clínica en Oncología Radioterapia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo de Investigación Clínica en Oncología Radioterapia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to show the non-inferiority of the incidental irradiation,
      as compared to intentional irradiation of the axillary nodes, in terms of 5-years
      disease-free survival (DFS) of early stage breast cancer patients with limited affectation of
      sentinel node assessed by OSNA (250 to 15,000 copies/uL), treated with breast-conservative
      surgery without axillary lymphadenectomy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Free Survival up to 5 years, defined as the time from randomization to the date of first documented progression (including local, regional or distant recurrence) or date of death from breast cancer, whichever comes first, up to 5 years.</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to loco-regional recurrence up 5-years</measure>
    <time_frame>5 years</time_frame>
    <description>Time to loco-regional recurrence up 5-years, defined as the time from randomization to the date of first documented (clinical or image-based) detection of tumour in treated breast (local recurrence), ipsilateral axilla or supraclavicular fossa (regional recurrence), whichever comes first, up to 5 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to distant recurrence up 5-years</measure>
    <time_frame>5 years</time_frame>
    <description>Time to distant recurrence up 5-years, defined as the time from randomization to the date of first documented (clinical or image-based) detection of noeplasic affectation of other organs or tissues different from the treated breast, ipsilateral axilla or supraclavicular fossa, whichever comes first, up to 5 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with acute toxicity, defined as any adverse event appearing up to one month after finalization of radiotherapy.</measure>
    <time_frame>7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with chronic tocixity, defined as any adverse event appearing during follow-up, up to 5 years.</measure>
    <time_frame>7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total irradiation dose (Gy) received in axillary levels I, II and III, supraclavicular fossa, and internal mammary chain volumes, at the end of radiotherapy.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1422</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Intentional irradiation of lymph nodes</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will receive a total dose of 50 Gy in the whole breast and nodal areas(axillary I, II, III, and supraclavicular) with optimization of the technique, in daily fractions of 2 Gy and 5 fractions/week during 5 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Incidental irradiation of lymph nodes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a total dose of 50 Gy in the whole breast, but not aimed at nodal areas, with optimization of the technique, in daily fractions of 2 Gy and 5 fractions/week during 5 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Irradiation</intervention_name>
    <description>Intentional versus incidental irradiation of lymphatic node areas, administered using a lineal accelerator, after 3D delimitation of the supraclavicular and axillary levels I, II and III. In both treatment arms, further tumoral bed boost will be allowed according to the investigator criteria, whether dose contribution to the nodal areas can be calculated. Due to its nature, interventions cannot be asked.</description>
    <arm_group_label>Intentional irradiation of lymph nodes</arm_group_label>
    <arm_group_label>Incidental irradiation of lymph nodes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Infiltrating, ductal carcinoma of the breast.

          2. Treated with conservative surgery (tumorectomy or quadrantectomy) without
             lymphadenectomy.

          3. Sentinel lymph node assessed by OSNA, with TTL in the range 250 - 15,000 copies/μL.

          4. Age ≥ 18 yrs old.

          5. Karnofsky Index ≥ 70 %.

          6. Signed Informed Consent.

        Exclusion Criteria:

          1. Other types of breast cancer different from infiltrating ductal carcinoma.

          2. Bilateral breast cancer.

          3. Males.

          4. Mastectomy or axillary homolateral lymph node dissection.

          5. Previous thoracic irradiation therapy.

          6. Systemic neoadjuvant therapy previous to surgery.

          7. Contraindications of radiotherapy (pregnancy, severe collagen diseases).

          8. Other neoplasms.

          9. Severe associated comorbidities that, according to the investigator criteria, may
             interfere with the study evaluations.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manuel Algara López, Medicine</last_name>
    <role>Principal Investigator</role>
    <affiliation>Grupo de Investigación Clínica en Oncología Radioterápica (GICOR)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manuel Algara López, Medicine</last_name>
    <phone>+34 933674144</phone>
    <email>malgara@parcdesalutmar.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centro Onoclógico de Galicia</name>
      <address>
        <city>A Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Inmaculada Díaz, Medicine</last_name>
      <phone>610524096</phone>
    </contact>
    <investigator>
      <last_name>Inmaculada Díaz, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de la Ribera</name>
      <address>
        <city>Alzira</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Soler, Medicine</last_name>
      <phone>962458485</phone>
    </contact>
    <investigator>
      <last_name>Miguel Soler, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manel Algara, Medicine</last_name>
      <phone>932483000</phone>
    </contact>
    <investigator>
      <last_name>Manel Algara, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Provincial de Castellón</name>
      <address>
        <city>Castellón</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inmaculada Beato, Medicine</last_name>
      <phone>964359700</phone>
    </contact>
    <investigator>
      <last_name>Inmaculada Beato, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Donostia</name>
      <address>
        <city>Donostia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Guimón, Medicine</last_name>
      <phone>943007275</phone>
    </contact>
    <investigator>
      <last_name>Elena Guimón, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de León</name>
      <address>
        <city>León</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Reyes Rodríguez Garrido, Medicine</last_name>
      <phone>987237400</phone>
      <phone_ext>42485</phone_ext>
    </contact>
    <investigator>
      <last_name>José Reyes Rodríguez Garrido, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ángel Montero, Medicine</last_name>
      <phone>913368000</phone>
    </contact>
    <investigator>
      <last_name>Ángel Montero, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Virgen de la Arrixaca</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio J Lozano Martínez, Medicine</last_name>
      <phone>626980234</phone>
    </contact>
    <investigator>
      <last_name>Antonio J Lozano Martínez, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Macarena</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco Carrasco, Medicine</last_name>
      <phone>600162156</phone>
    </contact>
    <investigator>
      <last_name>Francisco Carrasco, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose L López, Medicine</last_name>
      <phone>637220240</phone>
    </contact>
    <investigator>
      <last_name>Jose L López, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ester Jordà</last_name>
      <phone>961973500</phone>
    </contact>
    <investigator>
      <last_name>Ester Jordà, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Vigo</name>
      <address>
        <city>Vigo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María L López Louzara, Medicine</last_name>
      <phone>646914512</phone>
    </contact>
    <investigator>
      <last_name>María L López Louzara, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pilar Marcos, Medicine</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Araba</name>
      <address>
        <city>Vitoria</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Flaquer, Medicine</last_name>
      <phone>686166241</phone>
    </contact>
    <investigator>
      <last_name>Amanda Flaquer, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Velilla, Medicine</last_name>
      <phone>976765700</phone>
    </contact>
    <investigator>
      <last_name>Carmen Velilla, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paloma López Marín, Medicine</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reyes Ibáñez, Medicine</last_name>
      <phone>976765500</phone>
    </contact>
    <investigator>
      <last_name>Reyes Ibáñez, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manuela Lanzuela, Medicine</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Kiluk JV, Ly QP, Meade T, Ramos D, Reintgen DS, Dessureault S, Davis M, Shamehdi C, Cox CE. Axillary recurrence rate following negative sentinel node biopsy for invasive breast cancer: long-term follow-up. Ann Surg Oncol. 2011 Dec;18 Suppl 3:S339-42. doi: 10.1245/s10434-009-0704-1. Epub 2009 Sep 24.</citation>
    <PMID>19777181</PMID>
  </reference>
  <reference>
    <citation>Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans V, Godwin J, Gray R, Hicks C, James S, MacKinnon E, McGale P, McHugh T, Peto R, Taylor C, Wang Y; Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005 Dec 17;366(9503):2087-106. Review.</citation>
    <PMID>16360786</PMID>
  </reference>
  <reference>
    <citation>Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, Gray R, Pierce L, Whelan T, Wang Y, Peto R. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011 Nov 12;378(9804):1707-16. doi: 10.1016/S0140-6736(11)61629-2. Epub 2011 Oct 19. Review.</citation>
    <PMID>22019144</PMID>
  </reference>
  <reference>
    <citation>Ragaz J, Olivotto IA, Spinelli JJ, Phillips N, Jackson SM, Wilson KS, Knowling MA, Coppin CM, Weir L, Gelmon K, Le N, Durand R, Coldman AJ, Manji M. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst. 2005 Jan 19;97(2):116-26.</citation>
    <PMID>15657341</PMID>
  </reference>
  <reference>
    <citation>Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&amp;c randomized trials. Radiother Oncol. 2007 Mar;82(3):247-53. Epub 2007 Feb 15.</citation>
    <PMID>17306393</PMID>
  </reference>
  <reference>
    <citation>van Wely BJ, Teerenstra S, Schinagl DA, Aufenacker TJ, de Wilt JH, Strobbe LJ. Systematic review of the effect of external beam radiation therapy to the breast on axillary recurrence after negative sentinel lymph node biopsy. Br J Surg. 2011 Mar;98(3):326-33. doi: 10.1002/bjs.7360. Epub 2010 Nov 30. Review.</citation>
    <PMID>21254004</PMID>
  </reference>
  <reference>
    <citation>Peg V, Espinosa-Bravo M, Vieites B, Vilardell F, Antúnez JR, de Salas MS, Delgado-Sánchez JJ, Pinto W, Gozalbo F, Petit A, Sansano I, Del Mar Téllez M, Rubio IT. Intraoperative molecular analysis of total tumor load in sentinel lymph node: a new predictor of axillary status in early breast cancer patients. Breast Cancer Res Treat. 2013 May;139(1):87-93. doi: 10.1007/s10549-013-2524-z. Epub 2013 Apr 11.</citation>
    <PMID>23576079</PMID>
  </reference>
  <reference>
    <citation>Veronesi U, Orecchia R, Zurrida S, Galimberti V, Luini A, Veronesi P, Gatti G, D'Aiuto G, Cataliotti L, Paolucci R, Piccolo P, Massaioli N, Sismondi P, Rulli A, Lo Sardo F, Recalcati A, Terribile D, Acerbi A, Rotmensz N, Maisonneuve P. Avoiding axillary dissection in breast cancer surgery: a randomized trial to assess the role of axillary radiotherapy. Ann Oncol. 2005 Mar;16(3):383-8. Epub 2005 Jan 24.</citation>
    <PMID>15668261</PMID>
  </reference>
  <reference>
    <citation>Martelli G, Boracchi P, De Palo M, Pilotti S, Oriana S, Zucali R, Daidone MG, De Palo G. A randomized trial comparing axillary dissection to no axillary dissection in older patients with T1N0 breast cancer: results after 5 years of follow-up. Ann Surg. 2005 Jul;242(1):1-6; discussion 7-9.</citation>
    <PMID>15973094</PMID>
  </reference>
  <reference>
    <citation>Hwang RF, Gonzalez-Angulo AM, Yi M, Buchholz TA, Meric-Bernstam F, Kuerer HM, Babiera GV, Tereffe W, Liu DD, Hunt KK. Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection. Cancer. 2007 Aug 15;110(4):723-30.</citation>
    <PMID>17587208</PMID>
  </reference>
  <reference>
    <citation>Bilimoria KY, Bentrem DJ, Hansen NM, Bethke KP, Rademaker AW, Ko CY, Winchester DP, Winchester DJ. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol. 2009 Jun 20;27(18):2946-53. doi: 10.1200/JCO.2008.19.5750. Epub 2009 Apr 13.</citation>
    <PMID>19364968</PMID>
  </reference>
  <reference>
    <citation>Veronesi U, Viale G, Paganelli G, Zurrida S, Luini A, Galimberti V, Veronesi P, Intra M, Maisonneuve P, Zucca F, Gatti G, Mazzarol G, De Cicco C, Vezzoli D. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg. 2010 Apr;251(4):595-600. doi: 10.1097/SLA.0b013e3181c0e92a.</citation>
    <PMID>20195151</PMID>
  </reference>
  <reference>
    <citation>Caudle AS, Hunt KK, Kuerer HM, Meric-Bernstam F, Lucci A, Bedrosian I, Babiera GV, Hwang RF, Ross MI, Feig BW, Hoffman K, Litton JK, Sahin AA, Yang W, Hortobagyi GN, Buchholz TA, Mittendorf EA. Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 study: a practice-changing trial. Ann Surg Oncol. 2011 Sep;18(9):2407-12. doi: 10.1245/s10434-011-1593-7.</citation>
    <PMID>21327455</PMID>
  </reference>
  <reference>
    <citation>Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, Saha S, Hunt KK, Morrow M, Ballman K. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010 Sep;252(3):426-32; discussion 432-3. doi: 10.1097/SLA.0b013e3181f08f32.</citation>
    <PMID>20739842</PMID>
  </reference>
  <reference>
    <citation>Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, McCall LM, Morrow M. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011 Feb 9;305(6):569-75. doi: 10.1001/jama.2011.90.</citation>
    <PMID>21304082</PMID>
  </reference>
  <reference>
    <citation>Carlson RW, Hudis CA, Pritchard KI; National Comprehensive Cancer Network Breast Cancer Clinical Practice Guidelines in Oncology; American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors; St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations. J Natl Compr Canc Netw. 2006 Nov;4(10):971-9. Review.</citation>
    <PMID>17112447</PMID>
  </reference>
  <reference>
    <citation>Setton J, Cody H, Tan L, Morrow M, Hudis C, Catalano J, McCormick B, Powell S, Ho A. Radiation field design and regional control in sentinel lymph node-positive breast cancer patients with omission of axillary dissection. Cancer. 2012 Apr 15;118(8):1994-2003. doi: 10.1002/cncr.26504. Epub 2011 Aug 31.</citation>
    <PMID>21882186</PMID>
  </reference>
  <reference>
    <citation>Haffty BG, Hunt KK, Harris JR, Buchholz TA. Positive sentinel nodes without axillary dissection: implications for the radiation oncologist. J Clin Oncol. 2011 Dec 1;29(34):4479-81. doi: 10.1200/JCO.2011.36.1667. Epub 2011 Oct 31.</citation>
    <PMID>22042942</PMID>
  </reference>
  <reference>
    <citation>Bayo E, Herruzo I, Arenas M, Algara M. Consensus on the regional lymph nodes irradiation in breast cancer. Clin Transl Oncol. 2013 Oct;15(10):766-73. doi: 10.1007/s12094-013-1027-z. Epub 2013 Mar 22. Review.</citation>
    <PMID>23519538</PMID>
  </reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2014</study_first_submitted>
  <study_first_submitted_qc>January 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2015</study_first_posted>
  <last_update_submitted>September 15, 2015</last_update_submitted>
  <last_update_submitted_qc>September 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

